URGN — UroGen Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1668243 ·
Last close
$46.16
Market Cap
$2.26B
52W High
$50.81
52W Low
$26.00
ADV30
932,449
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 72,456,000 | 65,884,000 | 111,000 | -14,351,000 | 252,590,000 | 79,133,000 | 384,986,000 |
| Mar 2026 | 50,959,000 | 46,820,000 | -20,263,000 | -23,574,000 | 253,690,000 | 109,968,000 | 377,943,000 |
| Dec 2025 | 37,837,000 | 34,548,000 | -19,115,000 | -26,364,000 | 200,455,000 | 110,745,000 | 305,929,000 |
| Sep 2025 | 27,482,000 | 24,204,000 | -27,386,000 | -33,347,000 | 185,046,000 | 90,039,000 | 300,454,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,917,000
Investing CF
$40,100,000
Financing CF
$105,292,000
CapEx
$-218,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.98
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-997,641,000
Inventory
$24,589,000
Receivables
$88,757,000
ST Investments
$28,842,000
EBIT TTM
$-81,891,000
Pretax Income TTM
$-98,108,000
Interest Exp TTM
$16,217,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$188,734,000
EBITDA
$-66,345,000
Free Cash Flow
$-106,975,752
Enterprise Value
$2,378,696,192
Total Cash
$107,975,000
Total Debt
$196,128,000
Shares Out
48,880,564
Trailing EPS
$-1.97
Book Value
$-2.71
ROE
—
ROA
-18.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,788,000 | -124,863,000 | -153,494,000 | 200,455,000 | 305,929,000 | — | -162,444,000 |
| Dec 2024 | 90,398,000 | -96,782,000 | -126,874,000 | 285,711,000 | 294,514,000 | — | -96,766,000 |
| Dec 2023 | 82,713,000 | -65,536,000 | -102,244,000 | 178,311,000 | 243,523,000 | — | -76,376,000 |
| Dec 2022 | 64,357,000 | -79,041,000 | -109,783,000 | 135,619,000 | 224,980,000 | — | -87,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.79
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $2.24B | $38.50 | — |
| GENB | Generate Biomedicines, Inc. | $2.27B | $17.72 | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.23B | $25.27 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | $16.57 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
2026-08-21 13:55 · Yahoo
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
2026-08-20 11:05 · Yahoo
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
2026-08-20 11:00 · Yahoo
UroGen (URGN) Q2 2026 Earnings Call Transcript
2026-08-12 18:15 · Yahoo
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed
2026-08-09 16:12 · Yahoo
UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cysview Revenue Surges 73% as Net ...
2026-08-05 21:07 · Yahoo
Urogen Pharma Q2 Earnings Call Highlights
2026-08-05 20:04 · Yahoo
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-05 13:55 · Yahoo
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
2026-07-29 12:00 · Yahoo
Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today?
2026-07-22 03:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.